Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
NCT04777994
This study is recruiting at 13 US sites in 10 states, according to its ClinicalTrials.gov record last updated .
Summary
The study will assess the safety, PK, PD, and preliminary efficacy of ABBV-CLS-484 as monotherapy and in combination with a PD-1 targeting agent or with a or a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). The trial aims to establish a safe, tolerable, and efficacious dose of ABBV-CLS-484 as monotherapy and in combination. The study will be conducted in three parts. Part 1 Monotherapy Dose Escalation, Part 2 Combination Dose Escalation and Part 3 Dose Expansion (Monotherapy and Combination therapy).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Advanced Solid Tumor Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Calico Life Sciences LLC
- Last updated on ClinicalTrials.gov
- June 4, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- University of Arizona Cancer Center - Tucson /ID# 262698 · Tucson, AZ
Connecticut · 1
- Yale University School of Medicine /ID# 225707 · New Haven, CT
Maryland · 1
- Johns Hopkins Hospital /ID# 254056 · Baltimore, MD
Massachusetts · 2
- Beth Israel Deaconess Medical Center /ID# 252009 · Boston, MA
- Dana-Farber Cancer Institute /ID# 249642 · Boston, MA
Michigan · 1
- University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 252010 · Ann Arbor, MI
New York · 1
- NYU Laura and Isaac Perlmutter Cancer Center - 34th Street /ID# 257869 · New York, NY
North Carolina · 1
- Duke Cancer Center /ID# 251975 · Durham, NC
Pennsylvania · 2
- Perelman Center for Advanced Medicine /ID# 250188 · Philadelphia, PA
- UPMC Hillman Cancer Ctr /ID# 225706 · Pittsburgh, PA
Rhode Island · 1
- Lifespan Cancer Institute at Rhode Island Hospital /ID# 225705 · Providence, RI
Texas · 2
- University of Texas Southwestern Medical Center /ID# 251974 · Dallas, TX
- University of Texas MD Anderson Cancer Center /ID# 252004 · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.